Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has announced the acquisition of Ivers-Lee Group, a Swiss pharmaceutical assembly and packaging services provider. The acquisition integrates Ivers-Lee's operations into Alvotech's Technical Operations division while maintaining it as a separate legal entity.
The strategic move comes as Alvotech prepares to launch three new biosimilars in 2025. Ivers-Lee's GMP-licensed and FDA-approved facility in Burgdorf, Switzerland, along with its unit in L枚rrach, Germany, will provide capabilities including assembly and packaging of autoinjectors, pre-filled syringes, safety devices, and vials. Peter Sch眉pbach, Ivers-Lee's managing director, will join Alvotech's Technical Operations senior leadership team while continuing to lead Ivers-Lee.
Alvotech (NASDAQ: ALVO), un'azienda biotecnologica globale specializzata in medicinali biosimilari, ha annunciato l'acquisizione di Ivers-Lee Group, un fornitore svizzero di servizi di assemblaggio e confezionamento farmaceutico. L'acquisizione integra le operazioni di Ivers-Lee nella divisione Technical Operations di Alvotech, mantenendo per貌 la societ脿 come entit脿 legale separata.
Questa mossa strategica arriva mentre Alvotech si prepara a lanciare tre nuovi biosimilari nel 2025. La struttura autorizzata GMP e approvata dalla FDA di Ivers-Lee, situata a Burgdorf, in Svizzera, insieme all'unit脿 di L枚rrach, in Germania, offrir脿 capacit脿 di assemblaggio e confezionamento di autoiniettori, siringhe pre-riempite, dispositivi di sicurezza e fiale. Peter Sch眉pbach, direttore generale di Ivers-Lee, entrer脿 a far parte del team di leadership senior di Technical Operations di Alvotech, continuando a guidare Ivers-Lee.
Alvotech (NASDAQ: ALVO), una compa帽铆a biotecnol贸gica global centrada en medicamentos biosimilares, ha anunciado la adquisici贸n de Ivers-Lee Group, un proveedor suizo de servicios de ensamblaje y envasado farmac茅utico. La adquisici贸n integra las operaciones de Ivers-Lee en la divisi贸n de Operaciones T茅cnicas de Alvotech, manteni茅ndola como una entidad legal independiente.
Este movimiento estrat茅gico llega mientras Alvotech se prepara para lanzar tres nuevos biosimilares en 2025. La instalaci贸n con licencia GMP y aprobada por la FDA de Ivers-Lee en Burgdorf, Suiza, junto con su unidad en L枚rrach, Alemania, ofrecer谩 capacidades que incluyen el ensamblaje y envasado de autoinyectores, jeringas prellenadas, dispositivos de seguridad y viales. Peter Sch眉pbach, director general de Ivers-Lee, se unir谩 al equipo de liderazgo senior de Operaciones T茅cnicas de Alvotech, mientras contin煤a dirigiendo Ivers-Lee.
Alvotech (NASDAQ: ALVO)電� 氚旍澊鞓れ嫓氚�霟� 鞚橃暯頀堨棎 欷戩爯鞚� 霊� 旮�搿滊矊 氚旍澊鞓ろ厤 旮办梾鞙茧, 鞀れ渼鞀れ潣 鞝滌暯 臁半 氚� 韽灔 靹滊箘鞀� 鞝滉车鞐呾泊鞚� Ivers-Lee Group鞚� 鞚胳垬頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 鞚胳垬毳� 韱淀暣 Ivers-Lee鞚� 鞖挫榿鞚� Alvotech鞚� 旮办垹 鞖挫榿 攵�靹滌棎 韱淀暕霅橃毵� 氤勲弰鞚� 氩曥澑鞙茧 鞙犾霅╇媹雼�.
鞚� 鞝勲灥鞝� 瓴办爼鞚� Alvotech臧� 2025雲勳棎 靹� 臧�歆� 靸堧鞖� 氚旍澊鞓れ嫓氚�霟ゼ 於滌嫓頃� 欷�牍�毳� 頃橂姅 臧�鞖措嵃 鞚措（鞏挫鞀惦媹雼�. 鞀れ渼鞀� Burgdorf鞐� 鞙勳箻頃� GMP 鞚胳 氚� FDA 鞀轨澑 鞁滌劋瓿� 霃呾澕 L枚rrach鞐� 鞛堧姅 攵�靹滊姅 鞓ろ啝鞚胳牆韯�, 頂勲Μ頃勲摐 欤检偓旮�, 鞎堨爠 鞛レ箻 氚� 氚旍澊鞎岇潣 臁半 氚� 韽灔 鞐焿鞚� 鞝滉车頃╇媹雼�. Ivers-Lee鞚� 鞝勲鞚挫偓 Peter Sch眉pbach電� Alvotech 旮办垹 鞖挫榿 瓿犾渼 毽崝鞁� 韺�鞐� 頃╇頃橂┌, 霃欖嫓鞐� Ivers-Lee毳� 瓿勳啀 鞚措亴 鞓堨爼鞛呺媹雼�.
Alvotech (NASDAQ : ALVO), une soci茅t茅 biotechnologique mondiale sp茅cialis茅e dans les m茅dicaments biosimilaires, a annonc茅 l'acquisition de Ivers-Lee Group, un fournisseur suisse de services d'assemblage et d'emballage pharmaceutique. Cette acquisition int猫gre les op茅rations d'Ivers-Lee dans la division Technical Operations d'Alvotech tout en maintenant son statut d'entit茅 juridique distincte.
Cette d茅marche strat茅gique intervient alors qu'Alvotech se pr茅pare 脿 lancer trois nouveaux biosimilaires en 2025. L'installation agr茅茅e GMP et approuv茅e par la FDA d'Ivers-Lee 脿 Burgdorf, en Suisse, ainsi que son unit茅 脿 L枚rrach, en Allemagne, offriront des capacit茅s comprenant l'assemblage et l'emballage d'autoinjecteurs, de seringues pr茅remplies, de dispositifs de s茅curit茅 et de flacons. Peter Sch眉pbach, directeur g茅n茅ral d'Ivers-Lee, rejoindra l'茅quipe de direction senior des Technical Operations d'Alvotech tout en continuant 脿 diriger Ivers-Lee.
Alvotech (NASDAQ: ALVO), ein globales Biotechnologieunternehmen mit Fokus auf Biosimilars, hat die 脺bernahme von Ivers-Lee Group, einem Schweizer Anbieter von pharmazeutischen Montage- und Verpackungsdienstleistungen, bekanntgegeben. Die 脺bernahme integriert die Aktivit盲ten von Ivers-Lee in die Technical Operations-Abteilung von Alvotech, wobei Ivers-Lee als eigenst盲ndige juristische Einheit erhalten bleibt.
Dieser strategische Schritt erfolgt, w盲hrend sich Alvotech auf die Markteinf眉hrung von drei neuen Biosimilars im Jahr 2025 vorbereitet. Die GMP-lizenzierte und FDA-zugelassene Anlage von Ivers-Lee in Burgdorf, Schweiz, sowie die Einheit in L枚rrach, Deutschland, bieten Kapazit盲ten f眉r die Montage und Verpackung von Autoinjektoren, Fertigspritzen, Sicherheitsvorrichtungen und Fl盲schchen. Peter Sch眉pbach, Gesch盲ftsf眉hrer von Ivers-Lee, wird dem Senior Leadership Team der Technical Operations von Alvotech beitreten und weiterhin die Leitung von Ivers-Lee 眉bernehmen.
- Integration of a trusted partner with proven track record in assembly and packaging
- Expanded manufacturing capacity and flexibility to support three new biosimilar launches in 2025
- Addition of GMP-licensed and FDA-approved facilities in Switzerland and Germany
- Retention of key management with Peter Sch眉pbach joining Alvotech's leadership team
- Continued service to existing clients maintaining additional revenue streams
- Integration costs and operational challenges of merging two companies
- Potential risks associated with managing international operations across multiple sites
Insights
Alvotech's acquisition of Ivers-Lee strengthens vertical integration and expands packaging capacity ahead of three biosimilar launches in 2025.
Alvotech's acquisition of Ivers-Lee represents a strategic vertical integration that bolsters the company's assembly and packaging capabilities at a critical growth juncture. The timing is particularly significant as Alvotech prepares to launch three new biosimilars in 2025, requiring substantial packaging capacity to meet global market demands.
This acquisition transforms a preferred vendor relationship into an owned asset, giving Alvotech greater control over its supply chain and eliminating potential bottlenecks in the final stages of product commercialization. Ivers-Lee brings valuable regulatory credentials to the table鈥攂oth GMP licensing and FDA approval鈥攚hich typically represent significant hurdles for pharmaceutical manufacturing operations.
The integration of Ivers-Lee's specialized capabilities for assembling and packaging autoinjectors, pre-filled syringes, safety devices, and vials directly supports Alvotech's biosimilar portfolio. These delivery systems are essential for biological products, particularly those requiring precise dosing or self-administration.
Maintaining Ivers-Lee as a separate legal entity while integrating operations into Alvotech's Technical Operations division suggests a balanced approach that preserves existing business relationships and expertise while aligning the acquisition with Alvotech's strategic objectives. The decision to continue servicing external clients as a contract manufacturing organization (CMO) indicates an intention to maintain revenue streams beyond internal needs, potentially offsetting acquisition costs while maximizing facility utilization.
This acquisition represents a calculated step in Alvotech's vertical integration strategy, addressing a critical component in the biosimilar commercialization process. By bringing assembly and packaging capabilities in-house, Alvotech gains three distinct competitive advantages:
First, enhanced supply chain resilience. Converting a key vendor into an owned operation reduces dependence on third parties for essential finishing steps. This is particularly valuable given recent global supply chain disruptions that have plagued pharmaceutical companies.
Second, accelerated time-to-market capabilities. With three biosimilar launches planned for 2025, controlling the assembly and packaging processes allows for more responsive production scheduling and potentially faster market penetration.
Third, improved margin potential. While financial terms weren't disclosed, vertical integration typically yields cost efficiencies by eliminating vendor markups and enabling better coordination between manufacturing and packaging operations.
The retention of Ivers-Lee's management and continuation of its external client services demonstrates a pragmatic approach to the acquisition. This structure preserves established customer relationships and specialized expertise while potentially creating a revenue-generating unit within Alvotech's broader operations.
The acquisition also brings valuable regulatory approvals (GMP and FDA) and specialized capabilities for handling various delivery systems that are essential for biosimilars, which often require sophisticated delivery mechanisms like autoinjectors and pre-filled syringes to maintain competitive parity with reference products.
REYKJAVIK, Iceland and BURGDORF, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the expansion of its capacity for assembly and packaging with the acquisition of Ivers-Lee Group (鈥淚vers-Lee鈥�), a family owned business with headquarters in Burgdorf, Switzerland specializing in providing high-quality assembly and packaging services for the pharmaceutical sector. While Ivers-Lee will remain a separate legal entity, its operations will be integrated into Alvotech鈥檚 Technical Operations division, supporting Alvotech鈥檚 ambitious plans for growth.
鈥淚vers-Lee has been an Alvotech preferred partner in assembly and packaging for several years. We know and trust each other very well, having worked closely together. As Alvotech prepares for the launch of three new biosimilars in 2025 and sales growth in global markets, the integration of Ivers-Lee into our Technical Operations, provides added flexibility and capacity to meet increased global demand for our biosimilars, maintaining the highest level of quality and service,鈥� said Robert Wessman, founder, chairman and CEO of Alvotech.
Ivers-Lee was founded in Burgdorf, Switzerland in 1947, to supply innovative packaging services for the pharmaceutical sector. In addition to the site in Burgdorf, Ivers-Lee also operates a strategic business unit in L枚rrach, Germany.
Managing director Peter Sch眉pbach, grandson of Ivers-Lee鈥檚 founder, will remain managing director and member of the Board of Directors of Ivers-Lee Group. Furthermore, he will join the Technical Operations senior leadership team of Alvotech following the acquisition.
鈥淎lvotech offers the Ivers-Lee Group financial strength and development opportunities in a growth market, that we as a founding family cannot offer. This change brings stability both for Ivers-Lee and its employees,鈥� said Peter Sch眉pbach.
Ivers-Lee鈥檚 site in Burgdorf is GMP licensed, and FDA approved. Among the capabilities that will be integrated with Alvotech鈥檚 operations are assembly and packaging of autoinjectors, pre-filled syringes and safety devices and packaging of vials. Ivers-Lee has an international customer base and will also continue servicing other existing clients and providing CMO services, including blister and stick-pack activities as well as clinical supplies and QP services, provided by the unit in L枚rrach.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira庐 (adalimumab) and Stelara庐 (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech鈥檚 commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy鈥檚 (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit . None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our , and our or follow us on social media on , , , and .
Alvotech Forward-Looking Statements
Certain statements in this communication may be considered 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech鈥檚 expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as 鈥渕ay鈥�, 鈥渟hould鈥�, 鈥渆xpect鈥�, 鈥渋ntend鈥�, 鈥渨ill鈥�, 鈥渆stimate鈥�, 鈥渁nticipate鈥�, 鈥渂elieve鈥�, 鈥減redict鈥�, 鈥減otential鈥�, 鈥渁im鈥� or 鈥渃ontinue鈥�, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech鈥檚 control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to successfully integrate the operations of its subsidiaries with its core operations, including Ivers Lee; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech鈥檚 estimates of expenses and profitability; (6) Alvotech鈥檚 ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech鈥檚 partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech鈥檚 ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech鈥檚 current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech鈥檚 ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech鈥檚 ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech鈥檚 products and product candidates; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company鈥檚 business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled 鈥淩isk Factors鈥� and 鈥淐autionary Note Regarding Forward-Looking Statements鈥� in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
SWISS MEDIA CONTACT
Peter Sch眉pbach, MD Ivers-Lee
FAQ
What company did Alvotech (NASDAQ: ALVO) acquire in July 2025?
How many new biosimilars is Alvotech planning to launch in 2025?
What capabilities will Ivers-Lee bring to Alvotech's operations?
Will Ivers-Lee continue serving its existing clients after the Alvotech acquisition?
Who will lead Ivers-Lee following the acquisition by Alvotech?
